Gilde Healthcare announces successful sale of its outsourced specialist care provider Novicare to Gimv - Gilde Healthcare

Gilde Healthcare announces successful sale of its outsourced specialist care provider Novicare to Gimv

August 28, 2025
Utrecht (the Netherlands)

Gilde Healthcare, the specialized healthcare investor, has reached an agreement on the sale of its Dutch portfolio company Novicare to Gimv*. Novicare provides outsourced medical and paramedical (tele)care services. The company specializes in elderly care and disability care.

Under the active ownership of Gilde Healthcare, Novicare achieved significant growth, to date servicing 70 care institutions and 4,500 patients across the Netherlands. Gilde Healthcare and Novicare transformed Novicare’s patient centric service offering guided by a joint vision on enabling ‘better care at lower cost’. In addition to its strong presence in elderly care, the company expanded its services in disability care. Another milestone during the holding period was the launch of a pioneering telecare service, making high-quality, affordable care available in less populated areas of the Netherlands. Furthermore, Novicare strengthened its role as an industry thought leader, contributing to research, publications and conferences.

Novicare is centered around the healthcare professional. To support these professionals, Novicare provides an attractive working environment with a strong focus on personal development and flexibility. Furthermore, Novicare is active in the education of new professionals. The team grew to 250 professionals, cementing Novicare’s reputation as an employer of choice in the sector. To achieve its growth, Novicare also strengthened the management team.

Tom Klein Robbenhaar, Partner at Gilde Healthcare’s private equity fund, commented: “We are very proud of our partnership with Novicare. The investments in the team, new (tele)offerings and smarter operations have benefitted many patients and clients.”

Jet Wiechers and Wencke van der Meijden, CEO and Deputy-CEO at Novicare, commented: “We are proud that, with the support of Gilde Healthcare, we have consistently been able to work in a more innovative and effective manner. Doing so in a way that benefits our professionals, our partners, and our clients. By sharing this knowledge with the wider field, we have amplified our impact, and we will continue to do so in the future.”

*The transaction is subject to regulatory approval

About Novicare
Novicare provides outsourced specialist medical and paramedical (tele)care services for the elderly care and disabled care sectors in the Netherlands. It treats patients with complex and chronic conditions in both care institutions and domiciliary settings. The company’s multidisciplinary team comprises experts such as elderly care specialists, psychologists, physiotherapists, occupational therapists, speech therapists and dieticians. As one of the largest specialist care providers in elderly and disabled care in the Netherlands, Novicare is a knowledge center for all practitioners and healthcare institutions with which it collaborates. www.novicare.nl

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Private Equity and Venture&Growth. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medical technologies (MedTech) and therapeutics, based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com

More news

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
October 17, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025